Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis

Bone Marrow Transplant. 2014 Oct;49(10):1345-6. doi: 10.1038/bmt.2014.132. Epub 2014 Jun 23.

Authors

B Freeman¹, D Brauneis¹, D C Seldin¹, K Quillen¹, J M Sloan¹, A S Renteria¹, A C Shelton¹, T Teschner¹, K T Finn¹, V Sanchorawala¹

Affiliation

¹ Stem Cell Transplantation Program, Section of Hematology/Oncology, Boston Medical Center, Boston, MA, USA.

PMID: 24955784
DOI: 10.1038/bmt.2014.132

No abstract available

Publication types

Letter

MeSH terms

Amyloidosis / drug therapy*
Antineoplastic Agents, Alkylating / administration & dosage
Antineoplastic Agents, Alkylating / therapeutic use*
Hematopoietic Stem Cell Transplantation / methods*
Hospitalization / trends*
Humans
Immunoglobulin Light-chain Amyloidosis
Melphalan / administration & dosage
Melphalan / therapeutic use*
Retrospective Studies
Transplantation Conditioning / methods*

Substances

Antineoplastic Agents, Alkylating
Melphalan